Tech Coast Angels

Founded in 1997, Tech Coast Angels is the largest angel investor group in the United States. Its members provide funding and guidance to more early-stage high-growth companies in Southern California than any other investment group. TCA members invest in companies in a wide range of industries including life sciences, biotech and health IT. TCA has more than 325 members including its venture capital affiliates in five networks in Los Angeles Orange County San Diego Westlake/Santa Barbara and the Inland Empire. The organization will finance on an opportunistic basis as long as substantial disruptive market opportunities exists. The firm has historically invested in Biotech Therapeutics & Diagnostics, Biotechnology R&D Services, Biotechnology Other, Medical Technology companies with sub sectors of Anti-Infectives, Bioinformatics, CRO (Contract Research Organization), Diagnostic Instrumentation, Diagnostic Services, Drug Delivery, Food, Industrial Biotechnology, Small Molecules, Small Molecule Therapeutics, Wound Care and indications including Diseases of the Nervous System, Infectious and Parasitic Diseases, Neoplasms/Cancer/Oncology, Respiratory.

Websites:
www.greenwingsbiomedical.com
techcoastangels.com

Investor Type
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Richard Koffler
Member 

Teijin Pharma Ltd. United States

Teijin Pharma Ltd. has unique profiles managing pharmaceutical and home healthcare products and also strong value chaines from basic research to sales, maintenance and follow up to patients in both business divisions.

We are actively dedicating to look for opportunities to collaborate with the US companies including startups, instituites and investors to introduce products/technologies into JP market with some amounts of investments for the best collaborations.

We are focusing on areas of respiratory, cardiovascular, orthopedics, rehab and neurological diseases.

Mr Aki Maeda
Mr Aki Maeda
Manager of Business Development 

Texo Ventures United States

TEXO Ventures is a healthcare venture capital firm that was founded in 29 and is based in Austin Texas. The firm operates as a hybrid of angel and venture capital. The recent fund closed at $15.4 million in 212. The firm focuses on making equity investments in the Medical Technology and Healthcare IT spaces at near commercialization or early commercialization stage. The firm typically invests ranging from $3 million to $5 million into a company. The firm plans to make 2-3 investments over the next 6-9 month. TEXO Ventures is open to consider companies across the US. The firm primarily focuses on healthcare which includes Health IT Technology  enabled Health Services Chronic Disease Management Managed Care and Benefit Design. Although medical devices and functional diagnostics are considered for investment purposes Texo Ventures must see a clear regulatory pathway and obvious synergies with healthcare reform within a company. The firm's current investment portfolio includes companies in the area of medical technology. Within this field they are in areas such as diagnostic and therapeutic radiation devices electro mechanical medical devices re-usable instruments biomaterials and non-active implantable.

Philip Sanger
Managing Partner 

Torrey Pines Investment

Torrey Pines Investment (TPI) was founded in 22 and is based in San Diego CA. The firm has raised two funds and also invests in drug development via a partnership with BioMotiv. TPI makes venture-stage minority equity investments and prefers act as a co-investor but also leads rounds on occasion. The firm invests internationally.

Ron Demuth
President 

Twin Cities Angels Fund II, LLC United States

Twin Cities Angels is an angel group that was founded in 2006 that is based in Minnesota. The group has raised two funds that are The Twin Cities Angels Fund I and II. The second fund is currently looking to invest in emerging companies. The group typically provides seed and venture capital ranging from $ 25.000 to $2 million to life science companies. The group plans to invest in 4 to 6 companies per year. Twin Cities Angels seeks to invest in companies based in the Twin Cities Area of Minneapolis/St. Paul, the state of Minnesota and within a reasonable distance, such as Western Wisconsin, Northern Iowa, and Eastern Dakotas.

Year Founded
2006
Investor Type
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
John Alexander
Chairman & Founder 

TYLT Lab

TYLT Lab was founded in 213 and has offices in Santa Monica CA and in Hong Kong. TYLT Lab invests across a variety of sectors including biotech and medical technology and will be raising a second fund in 215. TYLT Lab typically invests $5-$1 million and prefers to invest in seed or Series A rounds. The firm makes up to 12 allocations per year and is interested in opportunities globally, companies developing products that can impact healthcare delivery in emerging markets such as China or India are of particular interest.
Gerard Casale
Managing Director 
Jagannath Samavedam
Senior Principal 

VisionScope Technologies United States

VisionScope Technologies (VSI) is an early stage medical device company utilizing state of the art video hardware, micro-optics (1.4mm) and advanced computational software to bring arthroscopic imaging to the surgeon’s office. The company’s VisionScope Imaging (VSI) system brings gold standard accuracy into the clinic, providing surgeons with direct visualization of patients’ joint space – views that could previously only be achieved in the operating room – providing better outcomes at a lower cost to both MRI and OR based diagnostics.

 Benefits of VSI:    

·     High definition quality of a VSI diagnostic can eliminate the need for a MRI and rule out OR based diagnostic surgery

·     More detailed and accurate than a MRI for joint conditions

·     Significantly reduces the cost of care for individuals and overall healthcare systems

·     Patient centric exam – the patient participates in treatment discussion

Website:
www.myvsi.com
Year Founded
2007
Main Sector
Medtech Subsector
Medtech Phase of Development
Technology Overview
A needle endoscope (1.4mm diameter) houses a miniature fiberscope which allows complete inter-capsular diagnostics in a physician office setting. The endoscope is gently inserted into the joint space (capsule) with pictures and video projected onto a monitor for both the physician and patient to observe. The diagnostic takes place in an office exam room with only a local anesthesia (Lidocaine.) The exam takes less than 10 minutes and requires no stitches or recovery time.
Alliance & Collaborations
None
Supporting Metrics or Evidence
A multi-center, prospective, blinded clinical trial compared the accuracy and efficacy of VSI to MRI and surgical arthroscopy in the diagnosis of knee pathologies. The results: VSI is statistically equivalent to surgical diagnostic arthroscopy (the gold standard) and significantly more detailed and accurate than MRI.
Current Financing Needs
Seeking equity investments
IP Status
24 Issued patents on the core technology
Recent Milestones
Pivotal trial presentation at AOSSM (American Orthopaedic Society for Sports Medicine)
Management Team Highlights
The leadership team has substantial orthopedics and med tech experience at Zimmer, Stryker, J&J DePuy (Hand Innovations), Intuitive Surgical and J&J Mitek (Innovasive Devices)
Hjalmar Pompe van Meerdervoort
CEO